Retail pharmacies: Biopharma’s bridge to better patient experiences and outcomes

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and personalized patient programs.

Jan. 27, 2025

Novo shares climb on early data for dual-acting obesity drug

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance. 

By Jonathan Gardner • Jan. 24, 2025

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

The biopharma industry outlook on 2025: Uncertainty and change

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats like competition from China.

By Ned Pagliarulo • Jan. 24, 2025

Mixed results for Keytruda; AbbVie to work with Neomorph

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and the FDA delayed a decision on Stealth’s Barth treatment.

By BioPharma Dive staff • Jan. 24, 2025

Senate sets date to vet RFK Jr.’s nomination to lead HHS

The Senate Finance Committee will meet on Jan. 29 to discuss the confirmation of RFK Jr., whose stances on vaccines and abortion have raised questions from Democrats and Republicans alike.  

By Kristin Jensen • Jan. 23, 2025

J&J joins Pfizer in detailing impact of Part D redesign

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

By Ned Pagliarulo • Jan. 22, 2025

J&J oncology sales grow, but shares slide on outlook

CEO Joaquin Duato said the company is positioned for sustained growth in coming years, due in good part to drugs like Darzalex and Carvykti. 

By Kristin Jensen • Jan. 22, 2025

Intellia makes progress on HAE study; 2 more China drug deals

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

By BioPharma Dive staff • Jan. 22, 2025

AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market opportunity analysts estimate to be worth about $500 million annually. 

By Jonathan Gardner • Jan. 21, 2025

What will 2025 hold for biopharma?

What does 2025 hold for pharma? Find out the top drugs, companies and therapy areas for the year ahead.

Jan. 21, 2025

Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

By BioPharma Dive staff • Jan. 17, 2025

‘The bar has risen’: China’s biotech gains push US companies to adapt

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive earlier this year.

By Ben Fidler • Jan. 16, 2025

Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

By Jacob Bell • Jan. 16, 2025

Lilly’s Omvoh approved by FDA for Crohn’s

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity. 

By Kristin Jensen • Jan. 16, 2025

JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

AbbVie's CEO hinted his company may be less willing to invest in psychiatry, while Lilly explained what it got wrong forecasting GLP-1 drug demand.

By Gwendolyn Wu , Jonathan Gardner , Ned Pagliarulo • Jan. 16, 2025

J&J files a potential blockbuster; Lykos shakes up its board

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong revenue numbers, while Bausch + Lomb made an acquisition.

By BioPharma Dive team • Jan. 15, 2025

JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

By Ben Fidler , Gwendolyn Wu , Jonathan Gardner • Jan. 14, 2025

Lilly blames slower-than-expected growth for 2024 sales miss

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.

By Jonathan Gardner • Jan. 14, 2025

JPM25: Deals, Summit’s bravado and gene therapy headwinds

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers after a difficult year. 

By Ben Fidler , Delilah Alvarado , Gwendolyn Wu • Updated Jan. 14, 2025

J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

By Ned Pagliarulo , Jacob Bell • Updated Jan. 13, 2025

Lack of regulatory harmonization and other challenges facing clinical services organizations in the APAC market

How clinical services organizations are overcoming challenges in the APAC market.

Jan. 13, 2025

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

By BioPharma Dive staff • Jan. 10, 2025

5 questions facing pharma in 2025

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

By Ned Pagliarulo , Jonathan Gardner , Delilah Alvarado • Jan. 9, 2025

Bayer says menopause drug succeeds in breast cancer study

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.

By Delilah Alvarado • Jan. 9, 2025

FDA adds warning to RSV shots from GSK, Pfizer

The regulator is requiring labeling that warns of Guillan-Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

By Delilah Alvarado • Jan. 8, 2025